SPX-302

SPX-302 is a preclinical-stage drug candidate being developed by SparX Biotech (also known as SparX Therapeutics). It is part of the company's pipeline of multi-specific antibody therapies designed for the treatment of solid tumors. While specific details regarding its molecular targets and mechanism of action have not been publicly disclosed, it belongs to the 300-series of assets at SparX, which typically includes bispecific antibody constructs (such as the LILRB2/PD-L1 bispecific SPX-303). The drug is developed using SparX's proprietary SAILING™ and SynMab™ platforms, which integrate AI-enabled target discovery with antibody engineering. As of 2024, SPX-302 remains in the discovery or early preclinical stage.